A1439
下垂体アデニル酸シクラーゼ活性化ポリペプチド-38
別名:
PACAP-38
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C203H331N63O53S
CAS番号:
分子量:
4534.26
UNSPSC Code:
41106305
NACRES:
NA.32
MDL number:
Form:
powder
Quality level:
form
powder
Quality Level
composition
Peptide content, ~70%
UniProt accession no.
storage temp.
−20°C
Gene Information
human ... ADCYAP1(116)
General description
Pituitary adenylate cyclase activating polypeptide-38 (PACAP38) is mapped to human chromosome 18. 27-residue-amidated fragment (PACAP27) comprises another isoform. The PACAP38 is major isoform associated with mammals.
Application
Pituitary adenylate cyclase activating polypeptide-38 has been used to test its effect in stimulating the formation of cyclic AMP hypothalamus and cerebral cortex slices of chicken and to treat glioblastoma cells (U87MG) in cell migration assay to test its anti-invasive effects.
Biochem/physiol Actions
PACAP-38 is a neuropeptide that has substantial sequence homology to vasoactive intestinal peptide (VIP). It is reported to serve as a neuronal survival factor.
Pituitary adenylate cyclase activating polypeptide-38 (PACAP38) is a cardioprotectant and may help in treating radiation-induced heart disease (RIHD). It plays a protective role during oxidative stress in cardiomyocytes. PACAP38 has antioxidant, anti-apoptotic and anti-inflammatory property. It is implicated in the pathophysiology of migraine and cluster headache.
Other Notes
Lyophilized from 0.1% TFA in H2O
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Eloisa Rubio-Beltrán et al.
The journal of headache and pain, 19(1), 64-64 (2018-08-09)
Pituitary adenylate cyclase activating polypeptide-38 (PACAP38) is a widely distributed neuropeptide involved in neuroprotection, neurodevelopment, nociception and inflammation. Moreover, PACAP38 is a potent inducer of migraine-like attacks, but the mechanism behind this has not been fully elucidated.Migraine is a neurovascular
J Kinhult et al.
The European respiratory journal, 15(2), 243-247 (2000-03-08)
Pituitary adenylate cyclase-activating peptide (PACAP) 38 displays several biological activities relevant to obstructive airway disease. In this study, the occurrence of PACAP 38 in human small bronchi and corresponding pulmonary arteries was analysed immunocytochemically. The dilatory effects of this peptide
Grazia Maugeri et al.
Biomedicines, 9(8) (2021-08-28)
Pituitary adenylate cyclase-activating polypeptide (PACAP) exerts different effects in various human cancer. In glioblastoma (GBM), PACAP has been shown to interfere with the hypoxic micro-environment through the modulation of hypoxia-inducible factors via PI3K/AKT and MAPK/ERK pathways inhibition. Considering that hypoxic
A J Martínez-Fuentes et al.
Endocrinology, 139(12), 5116-5124 (1998-12-01)
We have recently shown that the two bioactive forms of pituitary adenylate cyclase-activating polypeptide, PACAP38 and PACAP27, stimulate GH release and GH messenger RNA (mRNA) accumulation in cultured porcine pituitary cells. However, dose- and time-related differences in the response to
E M Lutz et al.
British journal of pharmacology, 128(4), 934-940 (1999-11-11)
1 The VPAC2 and PAC1 receptors are closely related members of the Group II G protein-coupled receptor family. At the VPAC2 receptor, VIP is equipotent to PACAP-38 in stimulating cyclic AMP production, whereas at the PAC1 receptor PACAP-38 is many
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）